Carcinoma ex pleomorphic adenoma: case report and options for systemic therapy

Current oncology

N. Chooback¹  C. Ho¹  J. Laskin¹  M. Martin¹  T. Thompson¹  M. Marra²  M. Jones²  K. Kasaian²  Y. Shen²  T. Ng³ 

[1] BC Cancer Agency;BC Cancer Research Centre;Vancouver Coastal Health Research Institute

关键词: Carcinoma ex pleomorphic adenoma;    chemotherapy;    cyclophosphamide;    doxorubicin;    cisplatin;   

DOI  :  10.3747/co.24.3588

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

The most common benign salivary tumour is a pleomorphic adenoma. Transformation to malignancy, carcinoma ex pleomorphic adenoma (cxpa), occurs in 6% of cases. Management focuses on surgical resection and radiotherapy; however, rare cases require systemic management. We present the case of a 60-year-old woman with a cxpa of the left parotid gland who required systemic therapy for locally recurrent disease. Treatment options were guided by the literature concerning malignant salivary gland tumour and by whole-genome and transcriptome sequencing of the tumour. The patient received multiple systemic agents during the course of her disease, with cyclophosphamide–doxorubicin–cisplatin providing the best control (partial response). Genomeand transcriptome-directed therapy, including sorafenib and vismodegib, were utilized with limited clinical benefit. Malignant transformation in cxpa is a complex process, and therapy directed at a single tumour pathway might not be sufficient to control disease.

【 授权许可】

Unknown